Pleuropulmonary disease associated with dopamine agonist therapy

Ann Neurol. 1991 Oct;30(4):613-6. doi: 10.1002/ana.410300416.

Abstract

Artificial dopamine agonists are widely employed for the treatment of idiopathic parkinsonism. Pleuropulmonary disease has previously been reported to occur with the use of bromocriptine and mesulergine. We report similar adverse effects induced by the newer agonists lisuride and cabergoline. All these agents are tetracyclic ergot derivatives. This suggests a causal link between ergot-derived dopamine agonists and pleuropulmonary disease.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cabergoline
  • Dopamine Agents / adverse effects*
  • Dopamine Agents / therapeutic use
  • Ergolines / adverse effects
  • Female
  • Humans
  • Lisuride / adverse effects
  • Lung Diseases / chemically induced*
  • Lung Diseases / diagnostic imaging
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Pleural Diseases / chemically induced*
  • Pleural Diseases / diagnostic imaging
  • Radiography

Substances

  • Dopamine Agents
  • Ergolines
  • Lisuride
  • Cabergoline